SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned a $150,000 milestone payment from SAGE Therapeutics (SAGE) relating to the earlier commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE), a life-threatening seizure condition in which the brain is in a state of persistent seizure.
Help employers find you! Check out all the jobs and post your resume.
